A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein

Effective treatments for respiratory syncytial virus (RSV) infection are lacking. Here, we report a human proof-of-concept study for RV521, a small-molecule antiviral inhibitor of the RSV-F protein. In this randomized, double-blind, placebo-controlled trial, healthy adults were challenged with RSV-A...

Descripción completa

Detalles Bibliográficos
Autores principales: DeVincenzo, John, Tait, Dereck, Efthimiou, John, Mori, Julie, Kim, Young-In, Thomas, Elaine, Wilson, Lynn, Harland, Rachel, Mathews, Neil, Cockerill, Stuart, Powell, Kenneth, Littler, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985722/
https://www.ncbi.nlm.nih.gov/pubmed/31712214
http://dx.doi.org/10.1128/AAC.01884-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985722/
https://www.ncbi.nlm.nih.gov/pubmed/31712214
http://dx.doi.org/10.1128/AAC.01884-19

Ejemplares similares